Hua’s China Deal With Bayer For Novel Oral Diabetes Drug Collapses

 
• By Dexter Jie Yan

Hua Medicine’s HuaTangNing (dorzagliatin), the world’s first approved glucokinase activator, has apparently fallen short of restoring Bayer to its pre-2020 frontrunner position in China’s market for oral type 2 diabetes drugs, and the two companies' alliance is now set to be dissolved.

Hua Medicine has decided to withdraw from a commercialization partnership with Bayer on HuaTangNing (dorzagliatin) in China. (Shutterstock)

More from Deals

More from Scrip